Delivery Order SPE2DB20D3103-SPE2DB25FP6P6
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 22, 2025, for the supply of Xolair 300 mg/2 mL autoinjector units valued at $3,188.32. This firm fixed price delivery order, with an ultimate completion date of August 12, 2025, represents a non-set-aside competitive award under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX). The pharmaceutical distributor, headquartered in Conshohocken, Pennsylvania,...
- The Defense Logistics Agency awarded a $3,188.32 firm fixed price delivery order to AmerisourceBergen Drug Corp on July 21, 2025, for Xolair 300 mg/2 ml auto-injector units, with completion targeted for August 11, 2025. This non-set-aside competitive award represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The product will be delivered from AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 21, 2025, for the supply of Xolair 300 mg/2 mL auto-injector vials valued at $3,188.32. This firm fixed-price delivery order is scheduled for completion by August 11, 2025, with performance taking place at the contractor's corporate office location in Conshohocken, Pennsylvania. The award was made through open competition with no set-aside designation, reflecting AmerisourceBergen's competitive...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 21, 2025, for the supply of Xolair 300 mg/2 mL auto-injectors with a ceiling value of $1,594.16 and a firm fixed price structure. The order is scheduled for completion by August 11, 2025, and will be fulfilled from the vendor's facility in Conshohocken, Pennsylvania. This delivery order is issued under a non-set-aside, competitive procurement process and represents a continuation of the pharmaceutical...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 21, 2025, for the supply of Xolair 75 mg/0.5 ml syringes with a ceiling value of $1,080.54 and a firm fixed price structure. This delivery order is non-set-aside and represents a competitively awarded contract with an ultimate completion date of August 11, 2025. The product will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 22, 2025, for the supply of Xolair 300 mg/2 mL auto-injector units. This competitively awarded, non-set-aside contract has a ceiling value of $63,766.40 with a firm fixed price structure and an ultimate completion date of August 12, 2025. The place of performance is the contractor's facility in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order on July 28, 2025, valued at $6,376.64 for Xolair 300 mg/2 mL auto-injector units. This firm fixed price, competitive delivery order is funded by the Defense Logistics Agency (DLA) and will be performed at the awardee's Conshohocken facility, with an ultimate completion date of August 18, 2025. No set-aside provisions were applied to this award. This delivery...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 18, 2025, for the supply of Xolair 300 mg/2 ml auto-injector units valued at $1,594.16. This is a firm fixed price delivery order with an ultimate completion date of August 8, 2025, and no set-aside designation was applied. The product will be delivered to the place of performance in Conshohocken, Pennsylvania, where AmerisourceBergen Drug Corp maintains its corporate headquarters. This delivery order...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for XOLAIR 300 mg/2 mL syringes with a ceiling value of $1,732.19. This competitively awarded, firm fixed-price contract was executed on July 23, 2025, with an ultimate completion date of August 13, 2025. The delivery order is being performed at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This contract represents a child order under a larger indefinite delivery contract vehicle,...
- The Defense Logistics Agency awarded a $3,601.70 delivery order to AmerisourceBergen Drug Corp on July 23, 2025, for Xolair 150 mg/mL syringes, with an ultimate completion date of August 13, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and is being performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical,...
- SPE2DB20D3103Indefinite Delivery Contract
- SPE2DB20D3103-SPE2DB25FP6P6Delivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of XOLAIR 300 mg/2 ml auto-injector prefilled syringes. This competitive award, valued at $3,188.32 with firm fixed pricing, is scheduled for completion by August 18, 2025. The contract represents a direct delivery order under AmerisourceBergen's existing Indefinite Delivery Contract vehicle with DLA Troop Support Medical. As a pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, AmerisourceBergen serves as a critical vendor for federal medical procurement, supplying brand-name and generic medications to military and veteran healthcare systems. This delivery order is issued as a child contract under AmerisourceBergen's comprehensive $999.999 billion Indefinite Delivery Contract (SPE2DX) with DLA Troop Support Medical, which extends through December 2026 and enables the company to supply pharmaceutical products and medical supplies globally to support military healthcare programs. The contract carries no set-aside designation and was competitively awarded through open procurement. XOLAIR (omalizumab) is a specialty biologic immunosuppressant medication used in the treatment of moderate-to-severe allergic asthma and other allergic conditions, reflecting the comprehensive therapeutic scope of medical products delivered through this federal contract vehicle.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.2k | 7/28/25 |